Vol 1 No 1 (2018): Proceedings on Cancer-Immuno-Oncology

DOI: https://doi.org/10.18416/CIO.2018.1810000

Immunogenicity / Biomarker

Human leukocyte antigens and haplotypes allow for prognostic classification of HNSCC patients
Gunnar Wichmann, Andreas Dietz, Susanne Wiegand

Immunogenicity / Biomarker, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810001 • DOI: 10.18416/CIO.2018.1810001

Article-Views: 351  |  PDF-Downloads: 193
Breaking the brake: targeting the immunosuppressive cells to optimize immunotherapy of cancer
Marco C. Merlano, Andrea Abbona, Ornella Garrone

Immunogenicity / Biomarker, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810002 • DOI: 10.18416/CIO.2018.1810002

Article-Views: 292  |  PDF-Downloads: 170
Immunotherapy and head and neck cancer: Focus on recurrent and metastatic disease
Robert Haddad

Immunogenicity / Biomarker, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810004 • DOI: 10.18416/CIO.2018.1810004

Article-Views: 280  |  PDF-Downloads: 167

Liquid Biopsy

Extracellular Vesicles as biomarkers for cancer progression and cancer associated VTE
Frank Gieseler, Fanny Ender

Liquid Biopsy, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810005 • DOI: 10.18416/CIO.2018.1810005

Article-Views: 295  |  PDF-Downloads: 125
Immune modulation by extracellular vesicles released from mesenchymal cells
Martina Seifert

Liquid Biopsy, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810006 • DOI: 10.18416/CIO.2018.1810006

Article-Views: 345  |  PDF-Downloads: 169

Cellular Vaccines

CAR NK cells for cancer retargeting
Ruth Esser, Ulrike Koehl, Wolfgang Glienke, Michael Morgan, Andrew Kaiser, Hinrich Abken, Michael Heuser, Krasimira Aleksandrova, Jana Leise, Olaf Oberschmidt, Christoph Priesner, Lubomir Arseniev, Axel Schambach, Stephan Kloess

Cellular Vaccines, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810009 • DOI: 10.18416/CIO.2018.1810009

Article-Views: 528  |  PDF-Downloads: 241
Immune biological rationale for the design of radioimmunotherapies
Udo S. Gaipl

Cellular Vaccines, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810010 • DOI: 10.18416/CIO.2018.1810010

Article-Views: 265  |  PDF-Downloads: 161
Role of resident memory T cells in cancer immunotherapy
Eric Tartour

Cellular Vaccines, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810011 • DOI: 10.18416/CIO.2018.1810011

Article-Views: 301  |  PDF-Downloads: 169
Perspectives of human gamma/delta T-cells in cancer immunotherapy
Dieter Kabelitz

Cellular Vaccines, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810012 • DOI: 10.18416/CIO.2018.1810012

Article-Views: 313  |  PDF-Downloads: 136

New Targets

On the development of personalized cancer vaccines
Hans-Georg Rammensee

New Targets, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810013 • DOI: 10.18416/CIO.2018.1810013

Article-Views: 274  |  PDF-Downloads: 157
Platelets regulate innate immunity in autoinflammatory diseases and cancer
Bernardo Simoes Franklin

New Targets, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810014 • DOI: 10.18416/CIO.2018.1810014

Article-Views: 279  |  PDF-Downloads: 165
A pan-cancer landscape of interactions between tumors and infiltrating immune cells
David Tamborero

New Targets, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810015 • DOI: 10.18416/CIO.2018.1810015

Article-Views: 324  |  PDF-Downloads: 177
Rediscovering an old story: HLA class I alterations and immune escape of tumors in the context of immunotherapies
Barbara Seliger

New Targets, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810029 • DOI: 10.18416/CIO.2018.1810029

Article-Views: 287  |  PDF-Downloads: 163
Biparatopic heavy chain antibodies (bi-hcAbs): fusion of two distinct CD38-specific nanobodies into a human IgG1 bi-hcAb results in potent CDC vs. myeloma cells
Kerstin Schütze, Julia Hambach, Katharina Petry, William Fumey, Birte Albrecht, Levin Schriewer, Jana Röckendorf, Stephan Menzel, Friedrich Haag, Catelijne Stortelers, Peter Bannas, Friedrich Koch-Nolte

New Targets, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810041 • DOI: 10.18416/CIO.2018.1810041

Article-Views: 349  |  PDF-Downloads: 188
Activation of MDA5 improves anti-tumor therapy and reduces suppressive capacity of myeloid-derived suppressor cells
Philipp Metzger, Sabrina V. Kirchleitner, Michael Kluge, Lars M. König, Stefan Endres, Caroline C. Friedel, Max Schnurr, Peter Duewell

New Targets, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810042 • DOI: 10.18416/CIO.2018.1810042

Article-Views: 365  |  PDF-Downloads: 165
Effect of both PD-1/PD-L1 and ERK inhibitor on Cisplatin-sensitive (HEY) and Cisplatin-resistant (HEY-Cis) ovarian cancer cell lines
Paulina Vogt, Frank Köster, Stephan Polack, Achim Rody, Karen Bräutigam

New Targets, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810043 • DOI: 10.18416/CIO.2018.1810043

Article-Views: 325  |  PDF-Downloads: 204
Effect of both PD-1/PD-L1 and ERK inhibitor on triple negative breast cancer cell lines and the non-triple negative cell line MCF-7
Elodie Kabore, Frank Köster, Stephan Polack, Achim Rody, Karen Bräutigam

New Targets, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810044 • DOI: 10.18416/CIO.2018.1810044

Article-Views: 339  |  PDF-Downloads: 197
Regulatory T cells in endogenous mouse lymphoma are antigen-specific nTregs and provide a target for immune checkpoint-inhibiting therapies
Vera Bauer, Fatima Ahmetlic, Tanja Riedel, Nico Trautwein, Tim Sparwasser, Stefan Stevanovic, Martin Röcken, Ralph Mocikat

New Targets, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810045 • DOI: 10.18416/CIO.2018.1810045

Article-Views: 354  |  PDF-Downloads: 196
Specific targeting of oncogenic mutations using CRISPR-technology to destroy activated oncogenes and enhance immune response
Felix Oppel, Matthias Schürmann, Holger Sudhoff

New Targets, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810046 • DOI: 10.18416/CIO.2018.1810046

Article-Views: 289  |  PDF-Downloads: 803

Microbiome

Tumor and host factors regulating anti-tumor immunity and immotherapy efficacy
Thomas F. Gajewski

Microbiome, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810019 • DOI: 10.18416/CIO.2018.1810019

Article-Views: 391  |  PDF-Downloads: 147

Resistance / Immunosuppression

MDSC as a new target for cancer immunotherapy
Viktor Umansky

Resistance / Immunosuppression, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810022 • DOI: 10.18416/CIO.2018.1810022

Article-Views: 261  |  PDF-Downloads: 168
Neo-adjuvant checkpoint inhibition – the pathway towards personalized immunotherapy
Christian Blank

Resistance / Immunosuppression, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810023 • DOI: 10.18416/CIO.2018.1810023

Article-Views: 317  |  PDF-Downloads: 173
Interference between tumor mutational burden, HPV status, immune signatures and outcome in patients with head and neck cancer treated with chemoradiotherapy: Results from a multicenter retrospective study of the German Cancer Consortium Radiation Oncology
I. Tinhofer, T. Eder, A. K. Hess, V. Fleischer, P. Balermpas, C. Rödel, A. Linge, M. Krause, M. Baumann, M. Stuschke, D. Zips, A. L. Grosu, A. Abdollahi, J. Debus, U. Ganswindt, C. Belka, S. Pigorsch, G. Multhoff, S. E. Combs, V. Budach

Resistance / Immunosuppression, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810024 • DOI: 10.18416/CIO.2018.1810024

Article-Views: 296  |  PDF-Downloads: 180

Combinational Strategies

Dynamics of conversation: Immunotherapy meets tumor microenvironment
Iris Helfrich

Combinational Strategies, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810025 • DOI: 10.18416/CIO.2018.1810025

Article-Views: 290  |  PDF-Downloads: 174
Modulating the tumor microenvironment
Dirk Jäger

Combinational Strategies, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810027 • DOI: 10.18416/CIO.2018.1810027

Article-Views: 227  |  PDF-Downloads: 142

Immunomodulation / Tumor Biology

Integrin β4 synergizes with E-and P-selectin to regulate tumor growth: Unravelling the molecular mechanisms
Sandra Hanika, Vera Labitzky, Florian Gebauer, Daniel Wicklein, Hanna Maar, Tobias Gosau, Jennifer Schröder-Schwarz, Stefan Linder, Kristoffer Riecken, Udo Schumacher, Tobias Lange

Immunomodulation / Tumor Biology, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810033 • DOI: 10.18416/CIO.2018.1810033

Article-Views: 328  |  PDF-Downloads: 171
Primary and recurrent head and neck squamous carcinomas are strikingly different regarding their immune microenvironment
Christian Watermann, Helen Pasternack, Christian Idel, Sven Perner, Rosemarie Krupar, Julika Ribbat-Idel, Mark Philipp Kühnel, Danny Jonigk, Johannes Brägelmann

Immunomodulation / Tumor Biology, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810035 • DOI: 10.18416/CIO.2018.1810035

Article-Views: 349  |  PDF-Downloads: 140
The role of NFATc1 in T cell-mediated immune responses during the development of lung cancer
Lisanne Heim, Juliane Friedrich, Marina Engelhardt, Denis I. Trufa, Carol I. Geppert, Ralf J. Rieker, Horia Sirbu, Susetta Finotto

Immunomodulation / Tumor Biology, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810036 • DOI: 10.18416/CIO.2018.1810036

Article-Views: 352  |  PDF-Downloads: 166
Role of glycolysis for intestinal inflammation and carcinogenesis
Jacob Hamm, Kenneth Klischies, Nina Sommer, Philip Rosenstiel, Felix Sommer

Immunomodulation / Tumor Biology, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810037 • DOI: 10.18416/CIO.2018.1810037

Article-Views: 287  |  PDF-Downloads: 171
MALDI-imaging: Identification of protein signatures of genomic instability in colorectal cancers
Timo Gemoll, Oliver Klein, Elena Miroll, Christoph Thorns, Jens Habermann

Immunomodulation / Tumor Biology, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810039 • DOI: 10.18416/CIO.2018.1810039

Article-Views: 294  |  PDF-Downloads: 173
Investigating a potential role of Got1 in T cell exhaustion.
Nina Weisshaar

Immunomodulation / Tumor Biology, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810040 • DOI: 10.18416/CIO.2018.1810040

Article-Views: 314  |  PDF-Downloads: 169

Therapy Prognosis / Prediction

Effects of EGFR-MEK-ERK pathway on PD-L1 expression in head and neck squamous cell carcinoma
Chao Rong, Bohai Feng, Marie Muller, Dana Holzinger, Christa Flechtenmacher, Julia Thierauf, Annette Affolter, Peter Plinkert, Jochen Hess

Therapy Prognosis / Prediction, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810047 • DOI: 10.18416/CIO.2018.1810047

Article-Views: 466  |  PDF-Downloads: 195
The emerging role of extracellular vesicles in clinical research inflammation, cancer progression, metastasis
Fanny Ender, Melanie Klee, Mario Kramer, Axel Merseburger, Ralph Pries, Gabriela Riemekasten, Achim Rody, Barbara Wollenberg, Frank Gieseler

Therapy Prognosis / Prediction, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810048 • DOI: 10.18416/CIO.2018.1810048

Article-Views: 299  |  PDF-Downloads: 171
CD8+ T cell response to HPV16 E7 predicts survival outcome in oropharyngeal cancer
Holger Sudhoff, Liam Masterson, Piyush Jani, Jane Carolyn Sterling, Peter Goon

Therapy Prognosis / Prediction, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810050 • DOI: 10.18416/CIO.2018.1810050

Article-Views: 270  |  PDF-Downloads: 157

Therapeutic Strategies / Approaches

Current status of radiotherapy/radiochemotherapy and immunotherapy combinations– a German survey
Lukas Käsmann, Chukwuka Eze, Olarn Roengvoraphoj, Claus Belka, Farkhad Manapov

Therapeutic Strategies / Approaches, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810051 • DOI: 10.18416/CIO.2018.1810051

Article-Views: 305  |  PDF-Downloads: 175
Activation of immune response in refractory patients to standard treatment (T.R.A.N.S.L.A.T.E.)
Andrea Abbona, Dario Sangiolo, Marco Merlano, Ornella Garrone, Merlotti Anna, Martino Monteverde, Cristiana Lo Nigro, Antonella Falletta, Marcella Occelli, Chiara Varamo, Massimo Aglietta, Loretta Gammaitoni, Alessia Reali

Therapeutic Strategies / Approaches, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810052 • DOI: 10.18416/CIO.2018.1810052

Article-Views: 292  |  PDF-Downloads: 148
Which adjuvants for tumor-antigen vaccination induce powerful non-sialylated IgG antibodies?
Yannic Bartsch, Marc Ehlers

Therapeutic Strategies / Approaches, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810053 • DOI: 10.18416/CIO.2018.1810053

Article-Views: 253  |  PDF-Downloads: 155
Killing melanoma cells with ROS provides immuno-protection against tumor growth in vivo
Eric Freund, Ramona Clemen, Rajesh Kumar Gandhirajan, Sander Bekeschus

Therapeutic Strategies / Approaches, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810055 • DOI: 10.18416/CIO.2018.1810055

Article-Views: 295  |  PDF-Downloads: 153
Pre- and intratherapeutic cellular monitoring for dose adjustment of chemotherapy in aggressive lymphoma
Julia Schröder, Stefan Rödiger, Madeleine Ruhe, P. Markus Deckert

Therapeutic Strategies / Approaches, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810056 • DOI: 10.18416/CIO.2018.1810056

Article-Views: 278  |  PDF-Downloads: 159
Combining anti-VEGF-A and anti-PD-L1 therapy prolongs overall survival in small cell lung carcinomas
Lydia Meder, Philipp Schuldt, Martin Thelen, Anna Schmitt, Felix Dietlein, Sebastian Klein, Sven Borchmann, Kerstin Wennhold, Ignacija Vlasic, Sebastian Oberbeck, Richard Riedel, Alexandra Florin, Kristina Golfmann, Hans A. Schlößer, Margarete Odenthal, Reinhard Büttner, Jürgen Wolf, Michael Hallek, Marco Herling, Michael von Bergwelt-Baildon, H. Christian Reinhardt, Roland T. Ullrich

Therapeutic Strategies / Approaches, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810057 • DOI: 10.18416/CIO.2018.1810057

Article-Views: 527  |  PDF-Downloads: 194
Robust GMP manufacturing process with IL-2 and a glycoprotein antibody cocktail generates highly active human NK cell batches for cancer immunotherapy
Katharina Bröker, Udo Schumacher, Ralf Pörtner, Hans Hoffmeister, Evgeny Sinelnikov, Stefan Lüth, Werner Dammermann

Therapeutic Strategies / Approaches, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810058 • DOI: 10.18416/CIO.2018.1810058

Article-Views: 308  |  PDF-Downloads: 160
Progression of head and neck cancer is associated with elevated neutrophil extracellular traps formation by circulating neutrophils
Anna-Sophie Decker, Ekaterina Pylaeva, Alexandra Brenzel, Sharareh Bordbari, Ilona Spyra, Stephan Lang, Jadwiga Jablonska

Therapeutic Strategies / Approaches, ID Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810059 • DOI: 10.18416/CIO.2018.1810059

Article-Views: 347  |  PDF-Downloads: 190
View All Issues